Upload
raanan
View
36
Download
0
Tags:
Embed Size (px)
DESCRIPTION
Prevention and Management of DM Complications. Shadi Al-Ahmadi. The Presentation will include:. Hypertension Dyslipidemia CVD Type 2 Diabetes-Associated Retinopathy Diabetic Periphral Neuropathy Diabetic Nephropathy. Hypertension. Facts: - PowerPoint PPT Presentation
Citation preview
Shadi Al-Ahmadi
The Presentation will include:HypertensionDyslipidemiaCVDType 2 Diabetes-Associated RetinopathyDiabetic Periphral NeuropathyDiabetic Nephropathy
HypertensionFacts: Seventy-three percent of adults with
diabetes have a blood pressure level of 130/80 mm Hg or
higher, or take prescription drugs to manage hypertension.
Concomitant hypertension augments the effects of hyperglycemia in microvascular complications.
HypertensionThe target blood pressure level goal for
individuals with type 2 diabetes should be less than 130/80 mm Hg .
Pharmacologic treatment: - ACE inhibitor. - When second drug is needed: - GFR > 50 Ml/min thiazide diuretic - GFR < 50 Ml/min loop diuretic
Dyslipidemia
We should attempt to lower the LDL cholestrol level to less than 100 mg/dL.
For patients with overt CVD and diabetes, an LDL cholesterol level of less than 70 mg/dL is recommended.
DyslipidemiaThe triglyceride level goal should be less than
150 mg/dL.
The HDL cholesterol level goal should be: - > 40 mg/dL for men. - > 50 mg/dL for women.
The statins are the drug class of choice for Lowering lipid levels in the management of type 2 diabetes.
Cardiovascular Disease55% of adult patients with diabetes have CVDAnnual assessment of Cardiovascular risk
factors is recommended.
In asymptomatic patients older than 40 years type 2 diabetes and another risk factor for coronary heart disease, treatment using a statin and aspirin is recommended.
Cardiovascular DiseaseSecondary prevention of CVD in patients with
type 2 diabetes include: - optimizing control of diabetes,
hypertension, body weight, and lipid levels. - ACE inhibitor - aspirin - statin - Beta blockers
Type 2 Diabetes-Associate Retinopathy
Diabetic retinopathy (DR) is a leading cause of vision loss in adults ages 20 to 74 years.
The prevalence is directly related to the length of lime a patient has diabetes.
The majority of patients with type 2 diabetes exhibit some degree of DR within 20 years of diagnosis.
Type 2 Diabetes-Associate Retinopathy
Although retinopathy typically develops approximately 5 years after hyperglycemia begins, many patients with type 2 diabetes with DR are undiagnosed for long periods.
The initial examination should be performed at the time of diabetes diagnosis. with subsequent examinations annually.
Type 2 Diabetes-Associate Retinopathy
Laser Phototherapy is a widely used therapy to manage DR.
It was found to decrease the risk of proliferative DR-induced vision loss from 15.9% to 6.4% in patients with diabetes.
Diabetic Periphral NeuropathyNeuropathies are some of the most common
long-term diabetic complications, with up to 47% of patients developing peripheral neuropathy (DPN).
Screening for peripheral neuropathy should be performed when the diagnosis of type 2 diabetes is made.
Patients should be screened annually thereafter.
Diabetic Periphral NeuropathyCurrent guidelines recommend an annual
comprehensive foot screening that should include:
- inspection and assessment of pulses. - assessment of protective sensation using
monofilament + one of the following: * 128-Hz tuning fork * ankle reflex testing. * pinprick sensation rest.
Diabetic Periphral NeuropathyManagement: Patients with DPN should receive enhanced
education regarding root care and special footwear.
Two drugs are FDA-approved to manage chronic pain associated with DPN .
Diabetic Periphral Neuropathy
Duloxetine (Cymbalta) is a ser0tonin norepinephrine reuptake inhibitor.
60 to 120 mg PO OD
Pregabalin (Lyrica) is an anti convulsant. 100 mg PO TID
Diabetic NephropathyDiabetes is a leading cause of ESRD.
Albuminuria is the earliest indicator of diabetic nephropathy.
Microalbuminuria is diagnosed when levels of urinary albumin exceed 30 mg/day or 20 mcg/min.
Diabetic Nephropathy20% to 40%0 of those with type 2 diabetes
and microaIbuminuria develop nephropathy.
But only 20% progress to ESRD within 20 years.
The urinary albumin level should be measured starting at diagnosis and then annually in patients with newly diagnosed type 2 diabetes.
Diabetic NephropathyMedical treatment include: - ACE Inhibitor - thiazide or loop diuretic.
Annual measurement of serum creatinine level to assess renal function and stage of chronic kidney disease is recommended.
THANK YOU